Is this acquisition directly by Merck & Co., Inc. (MRK)?

No, the filing indicates that the acquisition was completed by Schering-Plough Corporation, not directly by Merck & Co., Inc. This 8-K filing from Merck may be related in some other capacity or context not fully detailed within the provided snippet.

What were the main components of the acquired Organon BioSciences?

Organon BioSciences primarily consisted of Organon (human health), Intervet (animal health), Nobilon (human vaccine development), and Diosynth (a third-party manufacturing unit of Organon).

What was the financial size of this acquisition?

The acquisition was a substantial cash transaction, valued at approximately €11 billion.

What is the significance of this event for Merck investors?

While the acquisition was by Schering-Plough, for Merck investors, understanding this transaction is important as it significantly alters the competitive landscape and potential future strategic interactions within the pharmaceutical and animal health sectors. It might indicate shifts in market share, R&D focus, or potential future M&A activities involving key industry players.

MRK 8-K: Acquisitions & Dispositions

Summary

This 8-K filing from Merck & Co., Inc. (MRK), filed on November 26, 2007, relates to a significant event that occurred on November 19, 2007: the completion of Schering-Plough Corporation's acquisition of Organon BioSciences N.V. from Akzo Nobel N.V. for approximately €11 billion in cash. Organon BioSciences is a substantial entity, comprising a human health business (Organon), an animal health business (Intervet), a human vaccine development unit (Nobilon), and a third-party manufacturing unit (Diosynth).

Key Highlights

1Schering-Plough Corporation successfully closed the acquisition of Organon BioSciences N.V. from Akzo Nobel N.V.
2The acquisition was a significant cash transaction, valued at approximately €11 billion.
3Organon BioSciences includes the human health business, Organon.
4Organon BioSciences includes the animal health business, Intervet.
5The acquisition also encompasses Nobilon, a human vaccine development unit.
6The deal includes Diosynth, a third-party manufacturing unit affiliated with Organon.

Merck & Co., Inc. 8-K Report, Acquisition Completed (Nov 26, 2007)

Summary

Key Highlights

Frequently Asked Questions